Novonesis Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Novonesis hat ein Gesamteigenkapital von €11.0B und eine Gesamtverschuldung von €2.0B, wodurch sich der Verschuldungsgrad auf 18.1% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen €15.3B bzw. €4.2B. Novonesis Das EBIT des Unternehmens beträgt €525.0M, so dass der Zinsdeckungsgrad 15.7 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von €260.8M.

Wichtige Informationen

18.1%

Verhältnis von Schulden zu Eigenkapital

€1.99b

Verschuldung

Zinsdeckungsgrad	15.7x
Bargeld	€260.80m
Eigenkapital	€11.01b
Gesamtverbindlichkeiten	€4.25b
Gesamtvermögen	€15.25b

Jüngste Berichte zur Finanzlage

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 27

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 13

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Jun 13

Recent updates

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 27

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Sep 05

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Jul 09

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Jun 24

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

May 02

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Apr 07

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Mar 26

Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?

Mar 12

Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues

Feb 04

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Jan 29

Is Novozymes (CPH:NZYM B) Using Too Much Debt?

Dec 23

Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture

Dec 05

A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Oct 14

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 13

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Aug 29

Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Jul 13

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Jun 13

Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

May 29

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: NSIS BDie kurzfristigen Aktiva des Unternehmens (€1.8B) übersteigen seine kurzfristigen Passiva (€1.6B).

Langfristige Verbindlichkeiten: NSIS BDie kurzfristigen Vermögenswerte des Unternehmens (€1.8B) decken seine langfristigen Verbindlichkeiten (€2.6B) nicht.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: NSIS BDie Nettoverschuldung im Verhältnis zum Eigenkapital (15.7%) wird als zufriedenstellend angesehen.

Schulden abbauen: NSIS B Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 36.2% auf 18.1% zurückgegangen.

Schuldendeckung: NSIS BDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (44.8%).

Zinsdeckung: NSIS BDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (15.7x Coverage) gut gedeckt.

Novonesis Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Is Novozymes (CPH:NZYM B) Using Too Much Debt?

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Recent updates

Novonesis A/S to Report First Half, 2025 Results on Aug 13, 2025

Novonesis A/S Announces Board Changes

Consensus EPS estimates fall by 12%

Consensus EPS estimates increase by 11%

Consensus EPS estimates fall by 20%

First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023)

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Consensus EPS estimates increase by 13%, revenue downgraded

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Consensus EPS estimates increase by 14%

Full year 2023 earnings: Revenues in line with analyst expectations

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings: Revenues exceed analyst expectations

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Now 21% undervalued after recent price drop

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Novozymes A/S Announces Change to the Executive Leadership Team

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?

Upcoming dividend of kr.6.00 per share at 1.8% yield

Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues

Independent Chairman recently bought kr.1.0m worth of stock

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Is Novozymes (CPH:NZYM B) Using Too Much Debt?

Investor sentiment deteriorated over the past week

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture

Less than half of directors are independent

Third quarter 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Consensus EPS estimates increase by 11%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022